ATOSATOSSA THERAPEUTICS, INC.vs its industry peers
A metric-by-metric comparison of ATOSSA THERAPEUTICS, INC. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATOSThis | $24M#6 | — | 0.9x#4 | 13623.6x#5 | -95.6%#5 | -36.3%#3 | -2112684.9%#5 | -129.6%#6 | — | — | — | — |
| AARD | $28M#1 | — | 0.4x#1 | — | — | -179.7%#7 | — | -77.0%#3 | — | — | -88.1%#3 | — |
| ABVC | $28M#2 | — | 2.7x#6 | 93.2x#4 | 0.0%#1 | -61.3%#5 | -2416.0%#4 | -76.9%#2 | -68.5%#2 | — | — | — |
| CELU | $27M#3 | — | — | 1.0x#1 | -51.0%#3 | -58.4%#4 | -230.9%#2 | — | -260.7%#3 | — | — | — |
| CPHI | $27M#4 | — | 0.7x#3 | 6.4x#3 | -8.5%#2 | 32.7%#1 | -78.2%#1 | -8.8%#1 | -7.7%#1 | 5#1 | -62.9%#1 | — |
| CRVO | $25M#5 | 0.0x#1 | 1.1x#5 | 6.2x#2 | -58.9%#4 | -65.6%#6 | -706.2%#3 | -117.5%#5 | -5165.9%#4 | — | -76.9%#2 | — |
| CNTX | $18M#7 | — | 0.5x#2 | — | — | -35.2%#2 | — | -94.6%#4 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice